Abstract
Multiple myeloma (MM) is due to the proliferation in the bone marrow of malignant plasmacells and accounts for about 10% of all hematological tumors. MM is the natural evolution of a monoclonal gammopathy of uncertain significance. Although the introduction of novel biological agents in the clinical practice has changed the natural history of the disease, MM remains incurable. MicroRNAs (miRNAs) are short non-coding RNAs that control cell functions through mRNA targeting. In the cancer setting, miRNAs have shown prognostic and predictive potentials. Several preclinical findings demonstrate their broad anticancer activities in various types of cancer, including MM. In this article, we provide an overview of the biology of miRNAs focusing on the role of miRNA deregulation in MM pathogenesis. These findings represent the basis to discuss the potential role of miRNAs as therapeutic agents against MM.
Keywords: Bone disease, microRNA, multiple myeloma, non-coding RNA, target therapy.
Current Pharmaceutical Biotechnology
Title:MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches
Volume: 15 Issue: 5
Author(s): Marco Rossi, Nicola Amodio, Maria Teresa Di Martino, Pierosandro Tagliaferri, Pierfrancesco Tassone and William C. Cho
Affiliation:
Keywords: Bone disease, microRNA, multiple myeloma, non-coding RNA, target therapy.
Abstract: Multiple myeloma (MM) is due to the proliferation in the bone marrow of malignant plasmacells and accounts for about 10% of all hematological tumors. MM is the natural evolution of a monoclonal gammopathy of uncertain significance. Although the introduction of novel biological agents in the clinical practice has changed the natural history of the disease, MM remains incurable. MicroRNAs (miRNAs) are short non-coding RNAs that control cell functions through mRNA targeting. In the cancer setting, miRNAs have shown prognostic and predictive potentials. Several preclinical findings demonstrate their broad anticancer activities in various types of cancer, including MM. In this article, we provide an overview of the biology of miRNAs focusing on the role of miRNA deregulation in MM pathogenesis. These findings represent the basis to discuss the potential role of miRNAs as therapeutic agents against MM.
Export Options
About this article
Cite this article as:
Rossi Marco, Amodio Nicola, Martino Teresa Di Maria, Tagliaferri Pierosandro, Tassone Pierfrancesco and Cho C. William, MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches, Current Pharmaceutical Biotechnology 2014; 15 (5) . https://dx.doi.org/10.2174/1389201015666140519104743
DOI https://dx.doi.org/10.2174/1389201015666140519104743 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Neuron Protection as a Therapeutic Target in Acute Ischemic Stroke
Current Topics in Medicinal Chemistry Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells
Current Pharmaceutical Design Rab5 in the Regulation of Cell Motility and Invasion
Current Protein & Peptide Science Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Macrocyclic Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Neuronal and Vascular Oxidative Stress in Alzheimers Disease
Current Neuropharmacology Oxidative stress and Parkinson’s disease: New hopes in treatment with herbal antioxidants
Current Pharmaceutical Design The NK-1 Receptor: A New Target in Cancer Therapy
Current Drug Targets Discovery of Selective Probes and Antagonists for G Protein-Coupled Receptors FPR/FPRL1 and GPR30
Current Topics in Medicinal Chemistry Recent Advances in Cancer Therapy: An Overview
Current Pharmaceutical Design N-3 (Omega-3) Polyunsaturated Fatty Acids in the Pathophysiology and Treatment of Depression: Pre-Clinical Evidence
CNS & Neurological Disorders - Drug Targets Levels of Estrogen Receptors α and β in Frontal Cortex of Patients with Alzheimers Disease: Relationship to Mini-Mental State Examination Scores
Current Alzheimer Research Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Nanomedicine: A New Frontier in Cancer Therapeutics
Current Drug Delivery Pleiotropic Effects of Cardioactive Glycosides
Current Medicinal Chemistry Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals
Current Drug Targets Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry